Display Settings:

Format

Send to:

Choose Destination
Clin Infect Dis. 2012 Feb;54 Suppl 1:S35-43. doi: 10.1093/cid/cir880.

A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007).

Collaborators (213)

Freimann C, Rispal P, Lewandowski E, Chouaki T, Dupont H, Damaj G, Mertl P, Six P, Bouchara J, Hitoto H, Ifrah N, Urban T, Carrelet T, Pellegrini J, Mosser A, Calmelet A, Braman F, Bordes D, Dussaucy A, Viel F, Grenouillet F, Blasco G, Legrand F, Navellou J, Plouvier E, Tavernier L, Kantelip B, Kostrzewa A, Couprie B, Bebear J, Blanchart E, De Gabory L, Dupon M, Deminière C, Comar L, Peslin N, Cauvin J, Ibara G, D'Alche-Gautier M, Duhamel C, Simons A, Canas F, Berger P, Frangi I, Denier P, Acher G, Barre M, Soler C, Bargues L, Brousse D, Perez J, Afonso J, Pons D, Bay J, Jacomet C, Dechelotte P, Bretagne S, Belhadj K, Quantin C, Caillot D, Derancourt M, Vogt J, Peresse J, Hornus E, Pinier Y, Gutnecht J, Pierchon F, Baron S, Fauconnier J, Lebeau B, Sahuc J, Courouble C, Morel P, Crenn D, Duquesne B, Sendid B, Berthon C, Coiteux V, Vergnenègre A, Ajzenberg D, Pommepuy I, Boubier J, Messy P, Bienvenu A, Francxois Y, Michallet M, Peix J, Al Jijakli T, Meyer M, Bertrand M, Bardou V, Giovannini M, Beylot B, Ranque S, Stein A, Masson S, Metellus P, Stoppa A, Fiacre A, Kassab G, Amghar G, Michelon-Meslé C, Rispail P, Durand L, Alzahouri K, Machouart M, Debourgogne A, Witz D, Chassagne J, Gerard A, Simon E, Carradot D, Antonioli D, Gay-Andrieu F, Corradini N, Daideri G, Gari-Toussaint M, Hyvernat H, Poiree M, Roger P, Lechiche C, Lachaud L, Garcia A, Labbe S, Decroix P, Saada M, Billotet C, Kauffman-Lacroix C, Godet C, Decup D, Blanc D, Daragon H, Toubas D, Nérot C, Fresnel A, Carsin X, Gangneux JP, Arvieux C, Rioux N, Satre E, Gineyt G, Fourre M, Rodrigues J, Trombert B, Vercherin P, Raberin H, Cornillon J, Lucht F, Pietri D, Miquel P, Binder F, Roeslin N, Letscher-Bru V, Dupeyron J, Herbrecht R, Leclerc C, Michel C, Redier H, Molinier L, Cassaing S, Alvarez M, Esposito L, Marchou B, Brousset X, Uro-Coste E, Vérin I, Patoz P, Alfandari S, Lemaire X, Yazdanpanah Y, Froment X, Sunder S, Chandenier J, Gyan E, Benaoudia F, Le Magny D, Kohler J, Journel H, Deleau J, Selles P, Sini F, Doucet-Populaire F, Savale L, Bouges-Michel C, Chochillon C, Brugière O, Wolff M, Joly V, Adle- Biassette H, Baixench M, Chatellier G, Cornet M, Péan Y, Meas T, Kania R, Lebihan C, Bougnoux M, Fekkar A, Datry A, Bodin L, Samson Y, Brethon B, Develoux M, Isnard F, Pons-Pouchelle H, Lacroix C, Ribaud P, Xhaard A, Bergeron-Lafaurie A, Marie O, Pavie J, Raffoux E, Parrot A.

Author information

  • 1Institut Pasteur, Unité de Mycologie Moléculaire, Centre National de Référence Mycologie et Antifongiques, 25 rue du Dr Roux, Paris, France.

Abstract

BACKGROUND:

Mucormycosis is a deadly invasive fungal infection whose characteristics are only partially understood.

METHODS:

Data on mucormycosis obtained in France between 2005 and 2007 from 2 notification systems were merged. The 2008 European Organisation for Research and Treatment of Cancer/Mycoses Study Group definition criteria were applied and risk factors for death were analyzed by hazard ratios (HRs) calculated from the Cox proportional hazards regression model.

RESULTS:

A total of 101 cases (60 proven, 41 probable), mostly in men (58%) >50 years (mean age, 50.7 ± 19.9) were recorded. Hematological malignancies represented 50% (median time for occurrence, 8.8 months after disease onset), diabetes 23%, and trauma 18% of cases. Sites of infection were lungs (28%; 79% in hematology patients), rhinocerebral (25%; 64% in diabetic patients), skin (20%), and disseminated (18%). Median time between first symptoms and diagnosis was 2 weeks. The main fungal species were Rhizopus oryzae (32%) and Lichtheimia species (29%). In cases where the causative species was identified, R. oryzae was present in 85% of rhinocerebral forms compared with only 17% of nonrhinocerebral forms (P < .001). Treatment consisted of surgery in 59% and antifungals in 87% of cases (liposomal amphotericin B in 61%). Ninety-day survival was 56%; it was reduced in cases of dissemination compared with rhinocerebral (HR, 5.38 [2.0-14.1]; P < .001), pulmonary (HR, 2.2 [1.0-4.7]; P = .04), or skin localization (HR, 5.73 [1.9-17.5]; P = .002); survival was reduced in cases of hematological malignancies compared with diabetes mellitus (HR, 2.3 [1.0-5.2]; P < .05) or trauma (HR, 6.9 [1.6-28.6], P = .008) and if ≥2 underlying conditions (HR, 5.9 [1.8-19.0]; P = .004). Mucormycosis localization remained the only independent factor associated with survival.

CONCLUSIONS:

This 3-year study performed in one country shows the diverse clinical presentation of mucormycosis with a high prevalence of primary skin infection following trauma and a prognosis significantly influenced by localization.

PMID:
22247443
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk